Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders

Huckans, Marilyn; Loftis, Jennifer M.; Blackwell, Aaron D.; Linke, Alex; Hauser, Péter

doi:10.1186/1747-597x-2-4

Cited by 17 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once we isolated germane articles, we collected relevant data and parameter values. While many literature reviews on treatment adherence exist, most limit their analysis to categorical reviews: the number of studies finding some correlation are reported but the papers do not include quantitative analysis of the reported correlation strength (Huckans, Loftis, Blackwell, Linke, & Hauser, 2007;Simoni et al, 2006;Bottonari et al, 2010). Our literature review is not on par with a meta-analysis of the literature.…”

Section: Data Compilationmentioning

confidence: 99%

Modeling Hepatitis C treatment policy.

Kuypers¹,

L’Ambert²,

Moore³

et al. 2013

View full text Add to dashboard Cite

Chronic infection with Hepatitis C virus (HCV) results in cirrhosis, liver cancer and death. As the nation's largest provider of care for HCV, US Veterans Health Administration (VHA) invests extensive resources in the diagnosis and treatment of the disease. This report documents modeling and analysis of HCV treatment dynamics performed for the VHA aimed at improving service delivery efficiency. System dynamics modeling of disease treatment demonstrated the benefits of early detection and the role of comorbidities in disease progress and patient mortality. Preliminary modeling showed that adherence to rigorous treatment protocols is a primary determinant of treatment success. In depth meta-analysis revealed correlations of adherence and various psycho-social factors. This initial meta-analysis indicates areas where substantial improvement in patient outcomes can potentially result from VA programs which incorporate these factors into their design. 5 CONTENTS

show abstract

Section: Data Compilationmentioning

confidence: 99%

Modeling Hepatitis C treatment policy.

Kuypers¹,

L’Ambert²,

Moore³

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In addition, those with factors associated with increased risk of rapidly progressive liver disease, such as HIV/HCV or HBV/HCV co-infection, are also candidates for treatment. A large retrospective Veterans Administration study has shown that individuals who are diagnosed with a substance use disorder (SUD) complete and respond to interferon-based HCV treatment regimens at similar rates to veterans without SUD's ( Huckans et al 2007 ). Because individuals, including injection drug users, with acute HCV infection may be highly responsive to interferon therapy, consideration should be given to early treatment during acute HCV infection ( Calleri et al 2007 ; Corey et al 2006 ).…”

Section: Viral Hepatitis Infections Liver Disease and Injection Drugmentioning

confidence: 99%

“…Recently, more prospective, controlled clinical trials of standard-of-care treatments for HCV infection in patients who are injection drug users have been performed. In 2007, seven treatment trials were published that included injection drug users ( Belfiori et al 2007 ; Calleria et al 2007 ; DeRosa, et al 2007 ; Grebely et al 2007 ; Huckans et al 2007 ; Krook et al 2007 ; Schaefer et al 2007 ) while other studies investigated factors related to the successful treatment of injection drug users including drug-drug interactions with methadone ( Berk et al 2007 ; Gupta et al 2007 ), immune responses of injection drug users ( Sergi et al 2007 ), and medication adherence ( Sylvestre and Clements, 2007 ). More studies are needed to enhance the development of effective treatment programs and clinical guidelines.…”

Section: Treatment Of Viral Hepatitis Infection In the Context Of Phamentioning

confidence: 99%

Hepatitis Infection in the Treatment of Opioid Dependence and Abuse

et al. 2008

View full text Add to dashboard Cite

Many new and existing cases of viral hepatitis infections are related to injection drug use. Transmission of these infections can result directly from the use of injection equipment that is contaminated with blood containing the hepatitis B or C virus or through sexual contact with an infected individual. In the latter case, drug use can indirectly contribute to hepatitis transmission through the dis-inhibited at-risk behavior, that is, unprotected sex with an infected partner. Individuals who inject drugs are at-risk for infection from different hepatitis viruses, hepatitis A, B, or C. Those with chronic hepatitis B virus infection also face additional risk should they become co-infected with hepatitis D virus. Protection from the transmission of hepatitis viruses A and B is best achieved by vaccination. For those with a history of or who currently inject drugs, the medical management of viral hepatitis infection comprising screening, testing, counseling and providing care and treatment is evolving. Components of the medical management of hepatitis infection, for persons considering, initiating, or receiving pharmacologic therapy for opioid addiction include: testing for hepatitis B and C infections; education and counseling regarding at-risk behavior and hepatitis transmission, acute and chronic hepatitis infection, liver disease and its care and treatment; vaccination against hepatitis A and B infection; and integrative primary care as part of the comprehensive treatment approach for recovery from opioid abuse and dependence. In addition, participation in a peer support group as part of integrated medical care enhances treatment outcomes. Liver disease is highly prevalent in patient populations seeking recovery from opioid addiction or who are currently receiving pharmacotherapy for opioid addiction. Pharmacotherapy for opioid addiction is not a contraindication to evaluation, care, or treatment of liver disease due to hepatitis virus infection. Successful pharmacotherapy for opioid addiction stabilizes patients and improves patient compliance to care and treatment regimens as well as promotes good patient outcomes. Implementation and integration of effective hepatitis prevention programs, care programs, and treatment regimens in concert with the pharmacological therapy of opioid addiction can reduce the public health burdens of hepatitis and injection drug use.

show abstract

“…However, there is some evidence that treatment can be equally effective when patients have active psychiatric illness and drug use. 27-31 …”

Section: Introductionmentioning

confidence: 99%

Provider and Patient Correlates of Provider Decisions to Recommend HCV Treatment to HIV Co-Infected Patients

Wagner

Osilla

Garnett

et al. 2012

Journal of the International Association of Physicians in AIDS

View full text Add to dashboard Cite

Despite low uptake of HCV treatment among HIV co-infected patients, few studies have examined the factors that contribute to provider decisions to recommend treatment. Surveys of 173 co-infected patients and their primary care providers, as well as patient chart data, were collected at three HIV clinics in Los Angeles; 73% of the patients had any history of being recommended HCV treatment. Multivariate predictors of being offered treatment included being Caucasian, greater HCV knowledge, receiving depression treatment if depressed, and one's provider having a lower weekly patient load and more years working at the study site. These findings suggest that provider decisions to recommend HCV treatment are influenced by patient factors including race and psychosocial treatment readiness, as well as characteristics of their own practice and treatment philosophy. With changes to HCV treatment soon to emerge, further evaluation of factors influencing treatment decisions is needed to improve HCV treatment uptake.

show abstract

Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders

Cited by 17 publications

References 34 publications

Modeling Hepatitis C treatment policy.

Modeling Hepatitis C treatment policy.

Hepatitis Infection in the Treatment of Opioid Dependence and Abuse

Provider and Patient Correlates of Provider Decisions to Recommend HCV Treatment to HIV Co-Infected Patients

Contact Info

Product

Resources

About